Mabylon AG Nets $31.8M to Accelerate Next-Gen Allergen and Neurological Antibody Therapies

Mabylon AG is excited to announce a significant milestone in its journey of advancing innovative antibody-based treatments, having successfully raised 31,800,000 in its latest funding round. This substantial capital infusion will empower the private Swiss biotech company to further expand its pioneering work in combating severe allergies, inflammation, and neurological disorders. With a groundbreaking B-cell screening platform at its core, Mabylon AG has already demonstrated its ability to rapidly identify natural human antibodies that exhibit high specificity and remarkable therapeutic potential. A key focus of the current funding is the continued development of MY006, Mabylon AG’s first-in-class multispecific antibody therapeutic aimed at addressing peanut allergy—a market that is not only rapidly growing but also in dire need of novel therapeutic solutions. The raised funds will be strategically channeled towards scaling up research and development efforts, bolstering clinical trials, and enhancing manufacturing capabilities to meet the anticipated surge in demand for antibody-based therapies. Additionally, this investment will enable the company to expand its collaborative initiatives with leading research institutions and further optimize its unique screening platform to discover next-generation antibody therapies. By accelerating the development pipeline, Mabylon AG is well-positioned to transform available treatment options for patients suffering from severe allergic reactions and other complex diseases. This funding milestone not only validates the company’s innovative approach and potential impact but also paves the way for delivering transformative therapies to a broader patient community across the globe.